Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
4.12 USD | -1.20% | -3.07% | -25.45% |
05-15 | Earnings Flash (MRKR) MARKER THERAPEUTICS Reports Q1 Revenue $1.2M | MT |
04-30 | Ladenburg Thalmann Starts Marker Therapeutics With Buy Rating, $11 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-25.45% | 37.17M | |
+33.40% | 49.46B | |
+1.74% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.58% | 26.61B | |
-21.74% | 18.64B | |
+7.85% | 13.16B | |
+29.66% | 12.55B | |
+23.43% | 12.1B |
- Stock Market
- Equities
- MRKR Stock
- News Marker Therapeutics, Inc.
- Marker Therapeutics Says First Patient Dosed in Phase 1 Trial of Lymphoma Treatment